Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China
Authors:
- 13 October 2017
- journal article
- research article
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (1) , 79-86
Abstract
Background and Objective Tyrosine kinase inhibitors (TKIs) have obvious effects on chronic myeloid leukemia (CML), but they are expensive in China. Moreover, the overall cost of treatment of CML is high and the medical economic burden of patients with CML on the government is heavy. This study tested the cost effectiveness of imatinib, nilotinib, and dasatinib as first-line treatment in Chinese patients who were first diagnosed with chronic myeloid leukemia in the chronic phase (CML-CP). Methods A state-transition Markov model combining clinical effectiveness, utility, and cost data was used. Sensitivity analyses were conducted to determine the robustness of the model outcomes. Results The imatinib-first, dasatinib-first, and nilotinib-first strategy offered patients 9.76, 9.87, and 9.72 quality-adjusted life years (QALYs) at a cost of US$303,502.42, US$381,681.03, and US$305,509.92 over 20 years, respectively. The nilotinib-first strategy exhibited the lowest utility and highest price and was thus eliminated. An incremental cost-effectiveness analysis of the imatinib-first strategy and the dasatinib-first strategy showed that the dasatinib-first strategy yielded an incremental cost–utility ratio (ICER) of 710,714.64 $/QALY compared with the imatinib-first strategy, which exceeded the threshold; hence, the dasatinib-first strategy was not cost effective and was eliminated. The results were robust for multiple sensitivity analyses. Conclusion From the perspective of the Chinese medical system, imatinib is likely to be more cost effective than dasatinib and nilotinib for patients who were first diagnosed with CML-CP.Keywords
Funding Information
- Fujian Provincial Health and Family Planning Commission (2014-ZQN-JC-15)
- Fujian Provincial Health and Family Planning Commission (2015-CX-R4)
- Fujian Provincial Planning Office of Social Sciences (2014C042)
This publication has 25 references indexed in Scilit:
- Cost-Utility Analysis of Dasatinib and Nilotinib in Patients With Chronic Myeloid Leukemia Refractory to First-Line Treatment With Imatinib in ThailandClinical Therapeutics, 2014
- Efficacy and safety of dasatinib versus imatinib in the East Asian subpopulation of the DASISION trial of newly diagnosed chronic myeloid leukemia in chronic phaseLeukemia & Lymphoma, 2014
- Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib eraFrontiers of Medicine, 2012
- Cost-Effectiveness of Dasatinib and Nilotinib for Imatinib-Resistant or -Intolerant Chronic Phase Chronic Myeloid LeukemiaValue in Health, 2011
- Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib – a Swedish model applicationActa Oncologica, 2010
- Molecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-upAnnals of Hematology, 2008
- Outcome of patients with Philadelphia chromosome‐positive chronic myelogenous leukemia post‐imatinib mesylate failureCancer, 2007
- Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Value in Health, 2004
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998
- An assessment of the clinicohematological criteria for the accelerated phase of chronic myeloid leukemiaEuropean Journal of Haematology, 1996